Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis
Major bleeding · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 0.77 [0.39, 1.53]4 studies · 1055 participantsLow